BetterLife Pharma, Inc. (BETR) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.0 k

Shareholding (Dec 2023)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 8 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.07

Return on Equity

27.54%

Price to Book

-0.85

Revenue and Profits:

Net Sales:

(Quarterly Results - Apr 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-23.53%

6 Months

-35.0%

1 Year

-45.83%

2 Years

0.0%

3 Years

-62.86%

4 Years

-73.47%

5 Years

-92.93%

BetterLife Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

11.19%

EBIT to Interest (avg)

-3.94

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.10

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

ROE (avg)

0.95%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.85

EV to EBIT

-3.60

EV to EBITDA

-3.60

EV to Capital Employed

-0.99

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 90.00% vs -100.00% in Apr 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.50",
          "val2": "-2.30",
          "chgp": "78.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.20",
          "val2": "-2.00",
          "chgp": "90.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jan'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jan 2025 is 0.00% vs 0.00% in Jan 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jan 2025 is -24.14% vs 69.15% in Jan 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jan'25",
        "Jan'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.70",
          "val2": "-3.20",
          "chgp": "-46.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.90",
          "val2": "0.50",
          "chgp": "80.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.60",
          "val2": "-2.90",
          "chgp": "-24.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY

Apr'25

Apr'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.50

-2.30

78.26%

Interest

0.10

Exceptional Items

0.20

0.00

Consolidate Net Profit

-0.20

-2.00

90.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Consolidated Net Profit

YoY Growth in quarter ended Apr 2025 is 90.00% vs -100.00% in Apr 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jan'25

Jan'25

Jan'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.70

-3.20

-46.87%

Interest

0.30

0.10

200.00%

Exceptional Items

0.90

0.50

80.00%

Consolidate Net Profit

-3.60

-2.90

-24.14%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jan 2025 is 0.00% vs 0.00% in Jan 2024

Consolidated Net Profit

YoY Growth in year ended Jan 2025 is -24.14% vs 69.15% in Jan 2024

All Annual Results

Company CV

About BetterLife Pharma, Inc.

BetterLife Pharma, Inc.

Pharmaceuticals & Biotechnology

BetterLife Pharma Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of nutraceuticals and pharmaceuticals. Its products include AP-001, AP-002 and AP-003. AP-001 is a topical formulation of recombinant human Intensified high-dose intravenous interferon alpha 2b (IFNa2b) based on its Biphasix drug formulation technology. The Biphasix formulation allows stable cream formulation of IFNa2b and its delivery across the dermis/mucosa, with minimal systemic exposure. AP-001 is developed to treat human papillomavirus (HPV) induced cervical intraepithelial neoplasia (CIN). AP-002 is an organo-gallium complex whose drug substance is tris (8-quinolinolato) gallium (III). AP-002 has direct anti-tumor activity as well as direct anti-osteoclast activity. AP-003 is an IFNa2b inhalation formulation. The Company is also engaged in developing psychedelic compounds, peptides, pro-drugs and nutraceuticals.

Company Coordinates

Company Details

1275 WEST 6TH AVENUE , VANCOUVER BC : V6H 1A6

Tel: 1 438 8848841

https://pivotpharma.com/

Registrar Details